NASDAQ:BIOC
Delisted
Biocept Stock News
$0.435
+0 (+0%)
At Close: Jan 23, 2024
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Thursday, 01'st Apr 2021
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purc
Biocept to host webinar with leading neuro-oncologists to discuss its cerebrospinal fluid assay (CSF) for diagnosing and managing tumors
09:40am, Thursday, 01'st Apr 2021
Biocept Inc (NASDAQ:BIOC) (FRA:B003) will host a webinar featuring leading neuro-oncologists to discuss the use of its proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors th
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will host a webinar featuring leading neuro-oncologists to discuss t
BIOC Stock Price Increased Over 15% Pre-Market: Why It Happened
06:15am, Tuesday, 30'th Mar 2021
The stock price of Biocept Inc (NASDAQ: BIOC) has increased by over 15% pre-market. This is why it happened.
Biocept, Inc. (BIOC) CEO Michael Nall on Q4 2020 Results - Earnings Call Transcript
08:48pm, Monday, 29'th Mar 2021
Biocept, Inc. (BIOC) CEO Michael Nall on Q4 2020 Results - Earnings Call Transcript
Biocept posts first-ever quarterly profit and balloons 4Q revenue to $18.5M on strength of coronavirus testing
04:51pm, Monday, 29'th Mar 2021
Biocept Inc (NASDAQ:BIOC) swung to a profit in its fourth-quarter thanks to its coronavirus (COVID-19) testing driving revenue to $18.5 million. For the period ended December 31, 2020, the San Diego-b
Biocept: Q4 Earnings Insights
04:32pm, Monday, 29'th Mar 2021
Shares of Biocept (NASDAQ:BIOC) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 170.00% over the past year to $0.14, which beat t
Biocept changing the way physicians examine blood work for their cancer patients and doing coronavirus testing
01:24pm, Thursday, 18'th Mar 2021
Patented liquid biopsy technology called Target Selector detects cancer biomarkers Ramping up global marketing efforts for its blood tests and related products to grow organically Has received to da
3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy
11:41am, Tuesday, 16'th Mar 2021
Roche Holding AG (OTC: RHHBY) acquired GenMark Diagnostics, Inc (NASDAQ: GNMK) in a $1.8 billion deal on Monday, the same day Veracyte Inc (NASDAQ: VCYT) announced it completed the acquisition o
Biocept to Participate in Three Virtual Investment Conferences in March
07:00am, Tuesday, 09'th Mar 2021
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that President and CEO Michael Nall will participate in th
Biocept strikes supply agreement with Aegea Biotechnologies for co-developed ultra-sensitive coronavirus detection test
11:16am, Tuesday, 02'nd Mar 2021
Biocept Inc (NASDAQ:BIOC) and privately held life sciences company Aegea Biotechnologies Inc have announced a supply agreement for a new PCR-based coronavirus (COVID-19) assay kit designed by Aegea a
SAN DIEGO--(BUSINESS WIRE)--Aegea Biotechnologies & Biocept enter supply agreement to validate and commercialize new COVID-19 test to help screen, manage, and evaluate patients.
Biocept Inks Research Pact With Protean BioDiagnostics For Target Selector Kit Advantages In Lung Cancer
12:35pm, Tuesday, 23'rd Feb 2021
Biocept Inc (NASDAQ: BIOC) will collaborate with Protean BioDiagnostics Inc to research Biocept's Target Selector molecular assay's ability to determine EGFR status in non-small cell lung cancer
Biocept teams up with Protean BioDiagnostics to study Target Selector in determining EGFR mutations in tumor samples
10:32am, Tuesday, 23'rd Feb 2021
Biocept Inc (NASDAQ:BIOC) announced plans Tuesday to collaborate with Protean BioDiagnostics Inc to research the ability of its own Target Selector molecular assays to determine the status of EGFR mut
SAN DIEGO--(BUSINESS WIRE)--Biocept and Protean BioDiagnostics Collaborate to Demonstrate Advantages of Biocept's Target Selector Assay for Non-Small Cell Lung Cancer Patients.
